Previously Aired - May 25, 2021 Moderator: Featured panelists:
Director of Oncology Services, Chief of Medical Physics, Sarah Cannon Cancer Institute, Parkridge Medical Center, HCA Healthcare
Head of Neurosurgery branch of Neurology and Neurosurgery School MD Professor, Neurosurgeon at the European Medical Center in Moscow, Russia
Director of Neuro-oncology Chair and Professor, Department of Translational Neurosciences at Saint John's Cancer Institute in Santa Monica, CA
A study, under the guidance of Lead Investigator, Alexey Krivoshapkin, MD, PhD, a neurosurgeon at the European Medical Center (EMC) in Moscow, involved 28 patients with recurrent glioblastoma multiforme (GBM), who were treated between August 2016 and June 2019. All patients underwent maximal safe resection. Researchers concluded that IORT of recurrent GBM is feasible and provides encouraging local progression-free and overall survival, with a manageable toxicity profile. Discover how this new treatment option may offer patients time savings and quality of life benefits.
“We continue to be greatly encouraged by these clinical results and the benefits Brain IORT offers to patients with recurrent GBM,” said Professor Krivoshapkin. “There is no standard approach for treating patients with recurrent GBM and the repeated use of external beam radiation therapy (EBRT) in recurrent brain tumors is often limited by a relatively high risk of radiation toxicity. Brain IORT has the potential to deliver the required prescribed single focal dose that is equivalent to multiple sessions of EBRT, while minimizing radiation dose to neighboring healthy tissue."
Join Prof. Krivoshapkin, Dr. Kesari and Dr. Howard for an informative roundtable discussion on the benefits it offers to patients, physicians and the healthcare community.
Previously Aired - May 25, 2021
Sed ut perspiciatis unde omnis iste natus error sit voluptatem!
Nemo enim ipsam voluptatem quia voluptas sit odit aut fugit!
Ut enim ad minima veniam, quis nostrum exercitationem ullam!